TheraRadar
Clinical-Stage Companies / XOMA

XOMA

Pre-Approval PRO BETA
⚫

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 4/1/2016

18
Total Trials
7
Phase 3
11
Phase 2
0
Recruiting
193
Score

Pipeline by Phase

Phase 3
7
Phase 2
11
Phase 1

Therapeutic Focus

Pyoderma Gangrenosum Uveitis Osteoarthritis Type 2 Diabetes Mellitus Hypoglycemia

Clinical Trials (18)

NCT01747538 Phase 3 TERMINATED

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

Started: 10/1/2012

NCT02318914 Phase 3 TERMINATED

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Started: 11/1/2014

NCT02315417 Phase 3 TERMINATED

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Started: 11/1/2014

NCT02326740 Phase 3 TERMINATED

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Started: 12/1/2014

NCT01684345 Phase 3 TERMINATED

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

Started: 8/1/2012

NCT02258867 Phase 3 TERMINATED

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

Started: 11/1/2014

NCT02258854 Phase 3 TERMINATED

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

Started: 3/1/2014

NCT02772718 Phase 2 COMPLETED

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

Started: 4/1/2016

NCT02604485 Phase 2 COMPLETED

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

Started: 10/1/2015

NCT01950312 Phase 2 COMPLETED

The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

Started: 8/1/2013

NCT01882504 Phase 2 COMPLETED

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Started: 5/1/2013

NCT00777816 Phase 2 SUSPENDED

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

Started: 2/1/2009

NCT01498874 Phase 2 COMPLETED

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Started: 12/1/2011

NCT01683396 Phase 2 COMPLETED

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Started: 7/1/2012

NCT00998699 Phase 2 COMPLETED

Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes

Started: 2/1/2010

NCT01882491 Phase 2 COMPLETED

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Started: 5/1/2013

NCT01144975 Phase 2 COMPLETED

Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Started: 5/1/2010

NCT01066715 Phase 2 COMPLETED

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Started: 1/1/2010

Drug Candidates

XOMA 358 single dose level A XOMA 358 single dose level B XOMA 358 single dose level C XOMA 358 multiple dose level 1 Cohort 1 Cohort 2 Cohort 3 Cohort 4 Placebo Dose 1 gevokizumab
Activity Status: Inactive
Last Trial Started: 4/1/2016
Last Trial Ended: 5/1/2021
Trials (12 months): 0
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.